KPM Analytics Publishes Second Edition of The Baker’s Quality Assurance Handbook

The free digital 200+ page guide helps bakers and millers respond to wheat variability, rising costs, the loss of master baker expertise, and the arrival of AI in production. 

WESTBOROUGH, Mass., Aug. 12, 2026 /PRNewswire/ — KPM Analytics, a global leader in scientific instrumentation for food quality and safety, today announced the release of the Second Edition of The KPM Baker’s Quality Assurance Handbook: The Keys for Mastering Baking Process Control. The handbook is available now as a free digital download at https://kpm.is/bakers-handbook.

The Second Edition arrives at a difficult moment for the baking and milling industry. Extreme weather events and regional conflicts have increased variability in wheat quality, while inflation, tariffs, and trade barriers continue to raise the cost of raw materials and energy. At the same time, consumers have limited capacity to absorb higher prices. Bakeries are therefore under pressure to reduce waste, avoid production interruptions, and hold product quality steady using ingredients that change more often than they did in the past.

Two additional pressures shape the new edition. The first is a widening knowledge gap. Many master bakers are retiring or moving to other industries, and the practical expertise they used to correct a process when something went wrong is leaving with them. The second is the rapid arrival of AI-driven tools. These technologies improve consistency and quality in measurable ways, but many organizations are being asked to adopt them quickly, before their teams fully understand how the tools work or what the data means.

“Objective measurement is how a baking operation protects itself when the variables keep changing,” said Yuegang Zhao, Chief Commercial Officer at KPM Analytics and co-editor of the handbook. “When you can quantify what your flour, your dough, and your finished product are doing, you no longer depend on a single person’s experience to make the right decision. That knowledge belongs to the whole team, and it stays with the company.”

The handbook is organized into six parts covering technical fundamentals:

• A comprehensive technical overview objective analytical tools used in milling and baking processes today
• Raw material and ingredient quality control
• Production process control
• Product inspection and food safety
• Success stories from some of the world’s top baking and milling brands
• Guidance on working with technology suppliers.

Topics include water absorption, dough proofing analysis, moisture and compositional analysis by near-infrared spectroscopy, flour and dough rheology, and the use of vision inspection and AI systems for process control and foreign material detection. It is written as a working resource rather than a rigid manual, so bakers and millers can adapt the methods to operations of any size, whether they are building a first formal quality assurance program or improving one that already exists.

New to this edition is an expanded set of customer case studies, including Domino’s Pizza, Bay State Milling, Richardson Milling USA, Puratos, Europe Snacks, Emmi Desserts, Wooden Bakery, and La Toque Angevine, an LDC subsidiary. Each account describes a specific quality problem, the measurement approach used to address it, and the result on the production floor.

“The KPM Analytics’ Applications and Marketing teams put a great deal of work into this edition, and what they captured comes directly from years of working alongside our customers on the production floor,” says Zhao.

The KPM Baker’s Quality Assurance Handbook, Second Edition can be downloaded at no cost at https://kpm.is/bakers-handbook. (a $35.99 USD value).

About KPM Analytics

KPM Analytics is a global leader in scientific instrumentation, providing analytical and vision inspection solutions to laboratories and industrial operators in the food, feed, agriculture, industrial and environmental sectors. KPM products have a long history of helping companies secure product quality, optimize production processes, and make confident, data-driven decisions through reliable solutions, supported by dedicated application expertise and local service.  Visit https://www.kpmanalytics.com to learn more. 

Media contacts:

Andy Dambeck

Product Marketing Manager

+1 774-399-0477

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kpm-analytics-publishes-second-edition-of-the-bakers-quality-assurance-handbook-302845426.html

Mach Travel Solutions Ltd Q1 FY27 Revenue Jumps 538% YoY to ₹144.33 Crore

PAT rises 307% YoY as diversified growth strategy gains momentum

NEW DELHI, Aug. 12, 2026 /PRNewswire/ — Mach Travel Solutions Limited (BSE: MACHLTD), formerly known as Mach Conferences & Events Limited, announced its unaudited Q1 FY27 results. Revenue from Operations stood at ₹144.33 crore, up 538% YoY, while PAT stood at ₹6.17 crore, up 307% YoY.

The Company also recorded Gross Merchandise Value (GMV) of approximately ₹252 crore, reflecting the scale of travel transactions handled across its diversified platform.

Mach continues its transformation from a predominantly MICE-focused organisation into a diversified, technology-enabled travel solutions platform spanning Corporate Travel, MICE, B2B, Leisure and Government & Institutional Projects, while also developing a B2C Online Travel Agency (OTA) platform.

During the quarter, Mach executed large domestic and international mandates, including MICE programmes across Oceania, and continued scaling Corporate Travel through long-term enterprise agreements. The Company has onboarded 100+ Corporate Travel clients since April 2026 and continued execution of major Government & Institutional Projects in India.

Commenting on the performance, Mr. Amit Bhatia, Chairman & Managing Director, said: 

“Q1 FY27 marks an important milestone in MACH’s journey. Our transformation into a diversified travel solutions platform is beginning to translate into financial performance and a broader revenue profile. We remain focused on scaling our businesses, deepening technology integration and expanding our customer base. With a strong pipeline across key business verticals, we enter the coming quarters with encouraging visibility.”

Consolidated Financial Highlights

About Mach Travel Solutions Limited

Incorporated in 2004, Mach Travel Solutions Limited is a BSE-listed technology-enabled travel solutions company providing end-to-end solutions across Corporate Travel, MICE, B2B, Leisure and Government & Institutional Projects. The Company is also developing a B2C OTA platform.

Safe Harbour

This release contains forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially. Mach Travel Solutions Limited undertakes no obligation to update such statements to reflect future events or circumstances.

Media Contact:

Mach Travel Solutions Limited 

Ms. Yashashvi Srivastava

Company Secretary                                           

Email: compliance@machtravel.com  

Website: machtravelsolutions.com 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/mach-travel-solutions-ltd-q1-fy27-revenue-jumps-538-yoy-to-144-33-crore-302849670.html

Kashmir’s stories and traditions come alive in Asian Paints’ Tribute to the Valley

~Transforms forty shikaras into floating works of art through its initiative ‘Aks-e-Kashmir’, and a landmark mural at the University of Kashmir under the 10^th chapter of Donate A Wall ~ 

SRINAGAR, India, Aug. 12, 2026 /PRNewswire/ — Few places in the world have captured hearts and imaginations across generations quite like Kashmir. Revered for centuries as ‘paradise on earth’, its true beauty lies not only in its breathtaking landscapes, but also in its people, the traditions they have preserved, and the artistry woven into everyday life. Inspired by this enduring spirit, Asian Paints, in collaboration with St+art Foundation and XXL Collective, has unveiled two landmark public art initiatives in Srinagar as a tribute to the Valley’s rich cultural heritage – Aks-e-Kashmir, which reimagines forty iconic shikaras on Dal Lake as floating works of art, and the Kashmir chapter of ‘Donate A Wall’, marking the tenth year of the public art initiative with a monumental mural at the University of Kashmir. These initiatives celebrate the stories, craftsmanship and living heritage that make Kashmir truly unique.

Aks-e-Kashmir: Forty Shikaras Become Floating Canvases of the Valley’s Stories

For generations, the shikara has been more than just a boat. It has been one of Kashmir’s most cherished symbols, offering visitors a glimpse into the Valley’s beauty, its way of life, and the stories that unfold along its waters. With Aks-e-Kashmir, Asian Paints, in collaboration with XXL Collective, has reimagined forty of these iconic shikaras as floating works of art that celebrate the many identities of Kashmir.

Inspired by the Valley’s rich artistic and cultural heritage, the collection brings together four contemporary artists Owais Ahmed, Sheehij Kaul, Zahra Javed and Shweta Sharma each exploring a distinct theme.

Every shikara has been designed as a complete artistic experience, with every material carefully chosen to celebrate its craftsmanship while bringing each artist’s vision to life. A Royale tribute comes to life with Asian Paints Royale Glitz, while Apcolite Premium Enamel adds a subtle shimmer to the artworks, allowing them to reflect the changing light on Dal Lake from bright sunshine to misty mornings and the shade of the chinar trees. The handcrafted wooden canopies and frames take inspiration from the palette of Asian Paints Wood Finish. Inside the shikara, Ador and Pure Royale fabrics add comfort and elegance through thoughtfully designed upholstery and furnishings that complement the artwork. Together, these elements transform every shikara into an immersive experience, inviting visitors to not only admire Kashmir’s beauty but also experience its stories, traditions and craftsmanship.

The initiative builds on Asian Paints’ long-standing association with Kashmir, following the Aks-e-Kashmir Shade Guide and the special edition Apex Ultima Kashmir Pack inspired by the region’s colours, textures and architecture.

Donate A Wall Comes to Kashmir, Marking Ten Years of a Movement

Complementing the floating art installation is the Kashmir chapter of Donate A Wall, Asian Paints flagship public art initiative celebrating a decade of transforming public spaces across India into cultural landmarks.

Created in collaboration with St+art Foundation and the University of Kashmir, the 11,500 sq. ft. mural transforms the façade of the iconic Allama Iqbal Library Building. Conceptualised by Srinagar-based architect, artist and urban planner Zoya Kashmiri and brought to life by local artists, the artwork draws inspiration from the University’s motto, “तमसो मा ज्योतिर्गमय” (From Darkness to Light), celebrating knowledge, imagination and cultural memory.

Created using Asian Paints Apex Ultima Protek, the mural is designed to withstand changing weather conditions while retaining its vibrancy for years to come. The University of Kashmir is the latest addition to Donate A Wall, which has transformed 24 public spaces across 18 cities over the past decade.

Speaking about the initiative, Amit Syngle, Managing Director & CEO, Asian Paints Ltd., said, “At Asian Paints, we’ve always believed that the most meaningful way to celebrate a place is by celebrating what makes it uniquely its own. Over the years, our regional initiatives have sought to honour the stories, traditions and cultural identities that define different parts of India – from celebrating Kolkata’s iconic yellow taxis as moving symbols of the city’s spirit to the shikaras that have created experiences inspired by the colours, culture and heritage of Kashmir. This tribute continues that journey. For centuries, Kashmir has inspired admiration not only for its extraordinary landscapes, but for the people, craftsmanship and traditions that have shaped its identity. Through Aks-e-Kashmir and the Kashmir chapter of Donate A Wall, we wanted to create something that belongs to the Valley and reflects its living heritage. We hope these initiatives invite both residents and visitors to experience Kashmir through its stories, its artistry and the remarkable cultural legacy that continues to inspire generations.” 

Arjun Bahl, Co-founder, St+art Foundation and XXL Collective, said, “Projects like Aks-e-Kashmir and the Donate A Wall mural at the University of Kashmir, which also marks a decade of the initiative, reflect our continued belief in taking art beyond conventional spaces and making it part of everyday public life. For XXL Collective, this has been about expanding the role of public art beyond walls and static sites and showing how design can enter living systems with sensitivity. While the mural carries forward the legacy of Donate A Wall, the reimagined shikaras on Dal Lake represent a new canvas for artistic expression rooted in Kashmir’s culture and traditions. We are grateful to Asian Paints for enabling a project of this scale, and to the artists, artisans, boat owners and production teams whose work has allowed these boats to become carriers of Kashmir’s stories in a renewed form.”

Prof. Nilofer Khan, Vice Chancellor, University of Kashmir, said: “We are delighted to partner with Asian Paints and St+art Foundation for the landmark tenth edition of ‘Donate A Wall’. The breathtaking mural on our Allama Iqbal Library façade brings our university’s motto – ‘From Darkness to Light’ – to life in a truly powerful way. This initiative does more than just transform our university’s architecture; it enriches our academic environment, instills a sense of pride in our student community, and celebrates Kashmir’s rich cultural heritage right at the heart of our campus.”

Asian Paints Limited:

Asian Paints is India’s leading paint and decor company and ranked among the top 8 coatings companies in the world with a consolidated turnover of ₹35,516 crore (₹355 billion) in FY’26 and with a market capitalization of approx. ₹2,627* billion. Asian Paints along with its subsidiaries have operations in 14 countries across the world with 25 paint manufacturing facilities, servicing consumers in over 60+ countries through Asian Paints, Apco Coatings, Asian Paints Berger, Asian Paints Causeway, SCIB Paints, Taubmans and Kadisco Asian Paints. Asian Paints also offers a wide range of Home Décor products and is an emerging strong player in the Home Improvement and Décor space in India.

Note: Market capitalization is as on June 15, 2026

For our email disclaimer please visit https://www.asianpaints.com/disclaimer.html#email

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/kashmirs-stories-and-traditions-come-alive-in-asian-paints-tribute-to-the-valley-302849672.html

Nexteer Reports Record First-Half 2026 Results

Customer Wins, Technology Milestones and Digital Transformation Advance Motion Control Leadership

AUBURN HILLS, Mich., Aug. 12, 2026 /PRNewswire/ — Nexteer Automotive (HK 1316) today announced its 2026 interim results, reporting record first-half performance driven by above-market growth, strategic customer wins and continued advancement of next-generation motion control technologies. Revenue for the period was US$2.3 billion, up 4% compared with the first half of 2025, while total customer bookings reached US$3.3 billion. New and conquest business represented 43% of total bookings, and China domestic OEMs (COEMs) accounted for approximately US$1.0 billion, or 30%, reinforcing Nexteer’s position as a trusted motion control partner to OEMs across major global markets. As Nexteer marks its 120th anniversary, the company continues to build on its legacy of innovation while accelerating digital transformation to help OEMs improve speed, efficiency, quality and cost competitiveness in an increasingly complex mobility landscape.

“Nexteer continued to demonstrate strong execution in the first half of 2026, supported by customer momentum, technology advancement and operational discipline,” said Robin Milavec, President, Global Chief Operating Officer and Executive Board Director, Nexteer Automotive. “Our ability to deliver innovative motion control solutions across global markets positions us well to create long-term value for customers and shareholders while strengthening our competitive position for the future.”

First Half 2026 Financial Results

Nexteer’s first half 2026 financial performance reflected disciplined execution amid continued global market volatility. Revenue of US$2.3 billion was a record for the first half, representing a 4% year-over-year increase and outpacing the market by 180 basis points. Profitability increased primarily due to continued operating performance improvement. Adjusted EBITDA was US$263 million or 11.3% of revenue with EBITDA margin increasing by 100 basis points compared to the first half of 2025. Net profit attributable to equity holders was US$86 million, representing a 35% increase compared to the prior year. Free cash flow was US$109 million, nearly three times the level achieved in the prior year period, reflecting stronger earnings, disciplined capital allocation and improved cash conversion.

Product Launch & Bookings Highlights

Nexteer launched 28 new customer programs during the first half of 2026 across multiple product lines, customers and vehicle segments. Of these launches, 26 were tied to new or conquest business, reflecting Nexteer’s strong competitive position and ability to translate market demand for advanced motion control solutions into future revenue growth. Key milestones included the company’s first two Steer-by-Wire production launches in China and Mexico and its first High-Output Column EPS launch in China, reinforcing Nexteer’s leadership in advanced steering technologies. Seventeen launches supported fully electric vehicle platforms, further demonstrating the scalability of Nexteer’s portfolio across EV, ICE, and mixed-propulsion applications.

Nexteer secured US$3.3 billion in new customer program bookings during the first half of 2026, with 43% representing new or conquest business. These wins reinforce the strength of Nexteer’s global motion control portfolio and provide a solid foundation for future growth. Highlights included Nexteer’s first Rack-Assist EPS win in Europe, along with additional Steer-by-Wire and Column EPS wins with Chinese OEMs. China domestic OEM bookings totaled approximately US$1.0 billion, reflecting continued growth in this important market while demonstrating Nexteer’s ability to secure strategic programs across key global regions.

Technical and Innovation Leadership

Nexteer continued to advance its by-wire chassis control and motion control portfolio, including software, steering, braking and driveline technologies that help OEMs address electrification, automation, efficiency and enhanced vehicle dynamics. Together, these solutions reinforce Nexteer’s position as a full-system motion control partner for traditional, electrified and software-defined vehicle platforms.

• Advancing its Electro-Mechanical Braking (EMB) to market-readiness, further strengthening Nexteer’s full-stack motion control portfolio spanning steering and braking functions.
• Earned recognition as a 2026 Automotive News PACE Pilot Award Finalist for its High Mount Direct Drive Steer-by-Wire Handwheel Actuator (HMDD), highlighting the technology’s potential to enable greater vehicle design freedom, flexible steering placement, enhanced steering feel and next-generation driver experiences.
• Accelerated enterprise-wide AI and digital transformation initiatives to improve efficiency, speed, scalability and organizational agility, while strengthening Nexteer’s global manufacturing network through advanced automation, digital manufacturing technologies, manufacturing intelligence and AI-enabled analytics that enhance productivity, quality and operational visibility.

Operational Strength Through a Global Footprint

Nexteer continued to strengthen its global manufacturing and technical footprint to support customer demand, improve operational efficiency and enhance long-term competitiveness.

• Strengthened its position in the high-growth Asia-Pacific market with March grand opening of its new manufacturing facility in Rayong, Thailand. The plant began mass production of its first CEPS program in May.
• Expanded local development and validation capabilities through the Changshu test track expansion in China, enabling higher-speed vehicle testing and advanced dynamic evaluations across EPS, Steer-by-Wire and EMB systems while supporting faster response to regional customer needs.
• Maintained focus on global supply-chain optimization, improved inventory management and disciplined operational execution, all essential to margin improvement and long-term resilience.

“We are focused on strengthening Nexteer’s business for the long term by aligning our technology investments, customer growth opportunities and operational initiatives with the future of mobility,” said Milavec. “As we mark 120 years of innovation, our first-half 2026 results reflect the strength of our strategy, the dedication of our global team and our ability to help OEMs move faster, operate more efficiently and compete with confidence.”

For more information, visit www.nexteer.com.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements and opinions contained within this press release are based on current plans, estimates and projections, and therefore involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Nexteer Automotive and its directors and employees assume (a) no obligation to correct or update the forward-looking statements or opinions contained in this press release; and (b) no liability in the event that any of the forward-looking statements or opinions do not materialize or turn out to be incorrect.

ABOUT NEXTEER AUTOMOTIVE

Nexteer Automotive (HK 1316) is a global leading motion control technology company accelerating mobility to be safe, green and exciting. Our innovative portfolio supports by-wire chassis control, including electric and hydraulic power steering systems, steer-by-wire and rear-wheel steering systems, steering columns and intermediate shafts, driveline systems, software solutions and brake-by-wire. The company solves motion control challenges across all megatrends – including electrification, software/connectivity, ADAS/automated driving and shared mobility – for global and domestic OEMs around the world including BMW, Ford, GM, RNM, Stellantis, Toyota and VW, as well as automakers in India and China including BYD, Xiaomi, ChangAn, Li Auto, Chery, Great Wall, Geely, Xpeng and others. www.nexteer.com    

Link to Nexteer Media Center

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/nexteer-reports-record-first-half-2026-results-302849526.html

Context Labs Enters Multi-Year Agreement with Trafigura and Acquires Kinertic to Power Carbon-Informed Commodities Trading

Industrial AI platform will connect primary emissions data to operating entities and trading desks in oil, gas and metals across Trafigura’s global portfolio

AMSTERDAM, Aug. 12, 2026 /PRNewswire/ — Context Labs B.V. (“Context Labs”), the industrial AI infrastructure company, today announced three connected transactions with Trafigura PTE Ltd (‘Trafigura’): the acquisition of Agora (Europe) Limited and its Kinertic carbon-intelligence platform, developed by Trafigura; a strategic equity investment by Trafigura in Context Labs; and a multi-year master services and platform license agreement under which Trafigura will deploy the combined platform across its commodity trading desks, including oil, gas, and metals.

Kinertic provides commodity producers, traders and buyers with a carbon intelligence platform integrated into their existing systems, connected with trade capture systems to map flows, aggregate portfolios, and generate regulatory and customer reports. By bringing Kinertic into the Context Labs AI solution family and connecting it to its trusted data infrastructure, traders will be able to see price, volume, logistics, and trusted carbon metrics in a single environment, directly in the tools they already use. With the EU Carbon Border Adjustment Mechanism (CBAM) in its definitive phase, default emissions values translate directly into cost on every in-scope cargo. As the EU Methane Regulation moves from reporting to enforcement, methane intensity becomes a market-access prerequisite for gas, LNG, and oil flowing into the EU. Verified, trade-specific carbon data is now a procurement and trading requirement, not a reporting afterthought.

As part of the transaction:

• Context Labs has acquired Agora (Europe) Limited, the Trafigura subsidiary that owns and operates the Kinertic platform.
• Trafigura has separately made a strategic equity investment in Context Labs to support continued platform development and integration of the Kinertic capabilities.
• Context Labs and Trafigura have entered into a multi-year platform license agreement with Trafigura to license the platform across multiple commodity trading desks.

Context Labs provides the digital trust infrastructure to reliably monitor and calculate carbon-intensity data for commodities; from production through transport to end-market. Context Labs makes industrial AI and carbon programs trusted, by turning raw inputs into governed, audit-ready outputs that create measurable enterprise value in compliance and commercial markets.

“The opportunity isn’t in generating more data, it’s in bringing context to the data our customers already have,” said Dan Harple, Founder and CEO of Context Labs. “Where others see disconnected datasets, we see the foundation for a new intelligence layer. By bringing Kinertic together with Context Labs AI and our asset-grade data infrastructure, we turn fragmented inputs into connected, verifiable knowledge, so every output is traceable to source, reproducible in process, and credible to inform pricing, manage risk, and guide capital allocation.”

“Carbon is now a core dimension of market risk and opportunity,” said Hannah Hauman, Global Head of Carbon Trading at Trafigura. “Our traders need the same level of accuracy on emissions that they have on price and logistics. Trafigura has been privileged to support Kinertic’s evolution into an industry-leading carbon reporting and analytics platform since inception. We are confident that Context Labs will build on that strong foundation and drive the platform’s continued growth.” 

“This combination is about moving carbon from a reporting exercise into a core market signal,” said Pelle Sommansson, CEO and Co-founder of Kinertic. “Together with Context Labs, we are enabling a new level of transparency, where carbon intensity becomes a trusted, measurable attribute in how energy is valued and traded.”

For commodity producers, traders, financiers and buyers, the combined Context Labs–Kinertic offering delivers:

• Carbon-informed trading: portfolio analytics, trade-flow builders, and reports that quantify carbon and methane intensity across the commodity value chain, enabling differentiated pricing, structured deals, and improved hedging.
• Industrial AI at scale: an AI-ready, provenance-rich data layer that connects IoT, operational, third-party, and certification data into a single emissions and attributes layer.
• Regulatory and reporting readiness: standardized, auditable outputs for EU Methane Regulation, the Carbon Border Adjustment Mechanism (CBAM), and other relevant disclosure regimes, including end-to-end product carbon footprint reporting.

About Context Labs BV

Context Labs is an enterprise data infrastructure platform that transforms complex data into continuously proven information. Its AI-enabled software helps industrial organizations turn fragmented operational and emissions data into trusted, auditable, and decision-ready intelligence for carbon management, compliance, and commercial use. The company was formed out of MIT (Massachusetts Institute of Technology) research and is led by a team that has been instrumental in the at-scale growth of the Internet through prior companies. Context Labs is located in Amsterdam, Cambridge, Mass., and Houston. Learn more at www.contextlabs.com

About Trafigura

Trafigura provides critical resources to the world. Founded over 30 years ago and owned by its employees, the Group is at the heart of global supply, using its deep understanding of commodity markets to make supply chains more efficient, secure and sustainable.

Working across a global network, the Group deploys infrastructure, logistics, financing and market expertise to move energy and commodities from where they are produced to where they are needed. By connecting producers and consumers, we bring resilience and trust to complex supply chains.

The business supplies the energy and commodities the world needs today, including oil and petroleum products, metals and minerals, gas and power, while investing in lower-carbon solutions for the future.

The Trafigura Group also comprises industrial assets and operating businesses including multi-metals producer Nyrstar, fuel storage and distribution company Puma Energy, fuel supplier and distributor Greenergy, and the Impala Terminals joint venture. The Group employs approximately 14,500 people, of which more than 1,400 are shareholders, and operates in over 150 countries.

Visit: www.trafigura.com

Media Contact

Organization: Context Labs

Email: press@contextlabs.com

Phone: 1-617-902-0932

Web: contextlabs.com/resources

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/context-labs-enters-multi-year-agreement-with-trafigura-and-acquires-kinertic-to-power-carbon-informed-commodities-trading-302849246.html

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ — Cypherpunk Technologies Inc., (Nasdaq: CYPH) (“Cypherpunk”), today reported financial results for the second quarter ended June 30, 2026.

“In the second quarter, Cypherpunk built upon the momentum established earlier this year through the disciplined execution of our Zcash digital asset treasury strategy, increasing our treasury holdings to 323,394.38 ZEC, and welcoming Dev Ojha, founder of Valar Group, as an Advisor,” said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. “Our Leap Therapeutics subsidiary reached alignment with the FDA on a proposed Phase 3 trial in a DKK1-high, second-line, metastatic colorectal cancer population, with objective response rate as the primary endpoint to support accelerated approval and overall survival to support full approval in the United States and registration globally. We are conducting a strategic process to determine the best path to advance sirexatamab, whether as an independently financed spin-out company or with a partner who shares our commitment to cancer patients.”

“In an increasingly AI-driven economy, the demand for true privacy is moving from a technical preference to a civilizational necessity. Our execution in the second quarter reinforces Cypherpunk’s conviction in Zcash as a foundational monetary asset. By growing our ZEC treasury, expanding our world-class advisory team, and continuing to back core infrastructure developers like ZODL, we are systematically positioning Cypherpunk to capture the long-term value of digital privacy adoption,” said Will McEvoy, Chief Investment Officer of Cypherpunk.

Cypherpunk Highlights:

• Zcash treasury holdings increased to 323,394.38 ZEC
  • As of August 11, 2026, Cypherpunk held a total of 323,394.38 ZEC at an average purchase price of $341.83, representing approximately 1.92% of the total circulating supply of the Zcash network.
  • ZEC is a digital currency that can be transmitted over a peer-to-peer payment system. Zcash uses a cryptographic method called “zero-knowledge proofs” to allow users to engage in financial transactions while maintaining greater privacy.
• Dev Ojha Appointed as an Advisor
• • Cypherpunk appointed Dev Ojha, the founder of Valar Group, a leading development and research team focused on the Zcash Network, as an Advisor. Valar Group has taken a significant role in developing Zakura, a high-performance full node software designed for massive scalability of Zcash, and on the Ironwood shielded pool. Dev also serves as an official ZIP Editor for Zcash protocol standards. Cypherpunk’s Advisory Team also includes: Arjun Khemani, Zcash key opinion leader; Josh Swihart, CEO of ZODL; Jeff Tiller, Chief of Staff of Gemini; and Zooko Wilcox, Founder of Zcash and Chief Product Officer at Shielded Labs.

Leap Therapeutics Subsidiary Highlights:

• Publication of randomized Phase 2 DeFianCe study in Clinical Cancer Research
  • Leap Therapeutics announced the publication of results from the randomized Phase 2 DeFianCe (NCT05480306) study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research. The publication, “Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial,” reported the complete efficacy, safety, and biomarker analyses from the study and details the statistical basis for the DKK1 biomarker finding.
  • The peer-reviewed analyses establish that, while the prespecified primary endpoint was not met in the intent-to-treat population, the benefit of sirexatamab increases as a patient’s baseline plasma DKK1 level rises — a relationship confirmed by independent statistical approaches and reinforced by the observation that high DKK1 predicts poorer outcomes on standard of care alone. Together, these findings define DKK1-high metastatic colorectal cancer (mCRC) as a biologically distinct population with high unmet need.
• Reached FDA alignment on registrational Phase 3 trial in DKK1-high colorectal cancer
  • Leap Therapeutics held a Type C meeting with the FDA to discuss the DeFianCe results and proposed registrational path for sirexatamab in DKK1-high, second-line mCRC. Leap presented its proposed Phase 3 trial design, and the FDA provided feedback supporting key elements of that design, including the use of a DKK1 biomarker-selected patient population and a dual-endpoint structure intended to support both accelerated and full approval.
  • Leap Therapeutics reached alignment with the FDA on a randomized, controlled Phase 3 trial evaluating sirexatamab in combination with investigator’s-choice fluoropyrimidine-based chemotherapy (FOLFIRI or mFOLFOX6) plus bevacizumab, compared with chemotherapy and bevacizumab alone. Approximately 270 patients with mCRC whose disease has progressed following one prior line of systemic therapy prospectively identified as DKK1-high using a baseline plasma DKK1 assay cut point are expected to be enrolled and randomized 1:1. Potential accelerated approval in the United States could be determined by objective response rate (ORR) in an initial group of approximately 160 patients, and overall survival (OS) will be evaluated in the full study population intended to support a filing for full approval in the United States and to support registration in markets outside the United States.
  • A blood-based companion diagnostic would be developed in parallel to identify DKK1-high patients in routine clinical practice.
• Sirexatamab received Fast Track designation from FDA
  • In May 2026, the FDA granted Fast Track designation to sirexatamab in combination with fluoropyrimidine plus oxaliplatin- or irinotecan-based chemotherapy and bevacizumab, for the treatment of patients with DKK1-high mCRC whose disease has progressed following one prior systemic therapy.
  • The Fast Track program is intended to facilitate the development and expedite the review of drug candidates and vaccines that treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from frequent communication with the FDA, in addition to a rolling submission of the marketing application.
• Business update
  • Leap Therapeutics has initiated a strategic process to identify the best path forward for sirexatamab and to secure the resources required to advance the program into Phase 3 development. The process is expected to consider a range of alternatives, which may include financing the program as an independent entity, or a strategic transaction with a pharmaceutical or biotechnology company, including a partnership, license, collaboration, sale, or other business combination.
  • There can be no assurance that the strategic process will result in any transaction or financing, or that any transaction or financing that is completed will be on terms favorable to the Company or its stockholders. The Company has not set a timetable for the conclusion of the process and does not intend to disclose developments unless and until it determines that further disclosure is appropriate or required.

Selected Second Quarter 2026 Financial Results

Net income was $39.4 million, or $0.18 per diluted share, for the second quarter of 2026, compared to a net loss of $16.6 million for the second quarter of 2025. The change was primarily due to a $46.0 million unrealized gain on the fair value of the Company’s ZEC treasury holdings during the second quarter of 2026, which are marked to market at the end of each period. During the second quarter of 2026, the price of ZEC increased from $243.35 to $400.09.

Research and development expenses were $0.2 million for the three months ended June 30, 2026, compared to $10.5 million for the same period in 2025. The decrease was primarily due to a decrease in clinical trial and manufacturing expenses due to the completion of the clinical trials, together with a decrease in payroll and related expenses associated with the 2025 reduction in force.

General and administrative expenses were $4.5 million for the three months ended June 30, 2026, compared to $1.8 million for the same period in 2025. The increase of $2.7 million for the three months ended June 30, 2026 was primarily due to a $1.7 million increase in stock-based compensation related to restricted stock units granted to general and administrative employees and directors in the fourth quarter of 2025, a $0.8 million increase in payroll and related expenses, and a $0.2 million increase in professional fees.

During the three months ended June 30, 2026, the Company recorded a $46.0 million unrealized gain on the change in fair value of the Company’s ZEC treasury holdings as the price of ZEC increased during the second quarter of 2026 from $243.35 to $400.09.

Cash and cash equivalents totaled $7.6 million on June 30, 2026, and ZEC treasury holdings, categorized as digital asset receivable, totaled $129.4 million based on the ZEC price of $400.09 on June 30, 2026.

About Cypherpunk

Cypherpunk Technologies is a privacy technology company. The Company’s mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through two primary strategies: accumulating Zcash (ZEC); and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer, continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements address various matters including statements relating to the value of the Company’s ZEC holdings, the investment in Zcash Open Development Labs (“ZODL”), or digital assets held or to be held by the Company, the expected future market, price, and liquidity of ZEC or other digital assets the Company acquires, the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the digital asset treasury strategy include, among others: (a) risks relating to the Company’s operations and business, including the highly volatile nature of the price of ZEC; (b) the risk that material changes in the price of ZEC, such as decreases in price, will result in significant changes to the Company’s financial statements, such as unrealized losses on fair value of ZEC holdings and net loss; (c) the risk that the price of the Company’s common stock may be highly correlated to the price of ZEC; (d) the risk that the Company will fail to realize the anticipated benefits of the ZEC digital asset treasury strategy or the investment in ZODL; (e) risks related to the custody of our ZEC and our reliance on Gemini Space Station and its affiliates for trading and custody services; (f) changes in business, market, financial, political and regulatory conditions; (g) risks related to increased competition in the industries in which the Company does and will operate; (h) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; (i) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and (j) the Company’s ability to comply with the continued listing requirements of the Nasdaq Capital Market.

With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but are not limited to: (i) the DeFianCe study did not meet its prespecified primary endpoint of progression-free survival in the intent-to-treat population; (ii) the DKK1 biomarker subgroup and interaction analyses were exploratory, were based on a limited number of patients, were not adjusted for multiplicity, and may not be replicated in a prospective clinical trial; (iii) the impact of imbalances between treatment arms in the DKK1 subgroups; (iv) the risk that alignment with the FDA on trial design does not constitute agreement that any trial will succeed or that any marketing application will be accepted or approved, and the FDA may change its position at any time; (v) accelerated approval, if pursued, requires that the surrogate endpoint be reasonably likely to predict clinical benefit and is subject to confirmatory trial requirements and possible withdrawal if such requirements are not satisfied; (vi) the Company’s ability to initiate or complete the Phase 3 trial on the anticipated timeline or at all; (vii) the Company’s ability to obtain additional capital to advance sirexatamab on acceptable terms or at all; (viii) that risk that the strategic process may not result in any transaction or financing, may be terminated at any time, and any resulting transaction may not be on terms favorable to the Company or its stockholders; (ix) the Company’s ability to develop and validate a companion diagnostic; (x) the success of competing therapies; (xi) the Company’s ability to secure manufacturing capacity for sirexatamab; and (xii) the Company’s ability to maintain and protect its intellectual property rights.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

CONTACT:

Douglas E. Onsi

President & Chief Executive Officer

Cypherpunk Technologies Inc.

617-714-0360

For Investors:

Matthew DeYoung

Investor Relations

Argot Partners

212-600-1902

leap@argotpartners.com

For Media:

Jacqueline Ortiz Ramsay

It Factor Strategies

954-294-3249

jacqueline@itfactorstrategies.com

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/cypherpunk-technologies-reports-second-quarter-2026-financial-results-302849071.html